The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03502694




Registration number
NCT03502694
Ethics application status
Date submitted
11/04/2018
Date registered
11/04/2018
Date last updated
14/11/2018

Titles & IDs
Public title
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
Scientific title
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Adult Subjects Infected With Human Metapneumovirus
Secondary ID [1] 0 0
2017-001696-22
Secondary ID [2] 0 0
CR108378
Universal Trial Number (UTN)
Trial acronym
STEP
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metapneumovirus 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Lumicitabine
Treatment: Drugs - Placebo

Experimental: Regimen A (Low-Dose Lumicitabine) - Participants will receive a single 750 milligram (mg) loading dose (LD) (Dose 1) of lumicitabine and matching placebo followed by nine 250 mg tablets as maintenance doses (MDs) (Doses 2 to 10) of lumicitabine and matching placebo administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).

Experimental: Regimen B (High-Dose Lumicitabine) - Participants will receive a single 1000 mg LD (Dose 1) of lumicitabine followed by nine 500 mg tablets as MDs (Doses 2 to 10) of lumicitabine and matching placebo tablet, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).

Placebo Comparator: Regimen C (Placebo) - Participants will receive a placebo LD (Dose 1) followed by nine MDs (Doses 2 to 10) of matching placebo, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).


Treatment: Drugs: Lumicitabine
Participants will receive loading dose and maintenance dose of lumicitabine tablets orally.

Treatment: Drugs: Placebo
Participants will receive matching placebo tablets orally.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Area Under the Concentration-Time Curve (AUC) of Human Metapneumovirus (hMPV) Viral Load - The AUC of hMPV ribonucleic acid (RNA) logarithm base 10 (log10) viral load (measured by quantitative real time reverse transcriptase polymerase chain reaction [qRT-PCR] in the mid-turbinate nasal swab specimens) is estimated by analyzing mean log10 viral load values over time using a restricted maximum likelihood based repeated measures approach.
Timepoint [1] 0 0
Baseline up to Day 7
Secondary outcome [1] 0 0
Number of Participants with Adverse Events as a Measure of Safety and Tolerability - An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Timepoint [1] 0 0
Up to 28 days
Secondary outcome [2] 0 0
Number of Participants with an Abnormal Physical Examination Findings (Height, Body Weight, Respiratory System, Nose, Ear, Throat, Facial and Neck Lymph Nodes, and Skin Examination) as a Measure of Safety and Tolerability - Number of participants with an abnormal physical examination will be reported. A complete physical examination (including all body systems, height [only at screening], and body weight measurement) or a directed physical examination including respiratory system, nose, ear, throat, facial and neck lymph nodes, and skin examination will be performed.
Timepoint [2] 0 0
Up to 28 days
Secondary outcome [3] 0 0
Number of Participants with an Abnormal Vital Signs/Peripheral Capillary Oxygen Saturation (SpO2) Reading as a Measure of Safety and Tolerability - Number of participants with abnormal vital signs (including body temperature, heart rate, respiratory rate, systolic blood pressure [SBP], diastolic blood pressure [DBP]), and SpO2 measurements will be reported.
Timepoint [3] 0 0
Up to 28 days
Secondary outcome [4] 0 0
Number of Participants with an Abnormal Electrocardiogram (ECG) Reading as a Measure of Safety and Tolerability - Number of participants with abnormal twelve-lead ECG will be reported.
Timepoint [4] 0 0
Up to 28 days
Secondary outcome [5] 0 0
Number of Participants with Clinical Laboratory Abnormalities as a Measure of Safety and Tolerability - Number of participants with clinical laboratory abnormalities (clinical laboratory tests include the following: hematology panel, serum chemistry panel, urinalysis, estimated glomerular filtration rate (GFR), urine pregnancy test (women only), and serum procalcitonin levels) will be reported.
Timepoint [5] 0 0
Up to 28 days
Secondary outcome [6] 0 0
Maximum Observed Plasma Concentration (Cmax) of JNJ-63549109 - The Cmax is the maximum observed plasma concentration of JNJ-63549109. JNJ-63549109 is the metabolite of lumicitabine.
Timepoint [6] 0 0
Dose 1: 0.5 to 1 hour postdose, and 2 to 3 hours postdose; Dose 2: predose, and 3 to 6 hours postdose; Dose 3 and 10: predose
Secondary outcome [7] 0 0
Concentration at 12 Hours Postdose (C12h) of JNJ-63549109 - The C12h is the predicted concentration of JNJ-63549109 at 12 hours postdose.
Timepoint [7] 0 0
Days 1, 2, and 5/6: 12 hours postdose
Secondary outcome [8] 0 0
Area Under the Plasma Concentration-Time Curve (AUC) of JNJ-63549109 - AUC is defined as area under plasma concentration-time curve.
Timepoint [8] 0 0
Dose 1: 0.5 to 1 hour postdose, and 2 to 3 hours postdose; Dose 2: predose, and 3 to 6 hours postdose; Dose 3 and 10: predose
Secondary outcome [9] 0 0
Ordinal Scale - The ordinal scale will be used to assess participant's status and consists of 6 categories that are exhaustive, mutually exclusive, and ordered, where: 1) Death, 2) Admitted to intensive care unit (ICU), 3) Non-ICU hospitalization requiring supplemental oxygen, 4) Non-ICU hospitalization not requiring supplemental oxygen, 5) Not hospitalized, unable to resume normal activities, 6) Not hospitalized, resumption of normal activities.
Timepoint [9] 0 0
Day of last dose (Day 5 or Day 6)
Secondary outcome [10] 0 0
Length of Hospital Stay from Admission to Discharge - The length of hospital stay from admission to discharge will be reported.
Timepoint [10] 0 0
From admission to discharge (Up to 28 days)
Secondary outcome [11] 0 0
Length of Hospital Stay from Admission to Readiness for Discharge - The length of hospital stay from admission to readiness for discharge will be reported.
Timepoint [11] 0 0
From admission to readiness for discharge discharge (Up to 28 days)
Secondary outcome [12] 0 0
Length of Hospital Stay from Study Treatment Initiation to Discharge - The length of hospital stay from study treatment initiation to discharge will be reported.
Timepoint [12] 0 0
From study treatment initiation to discharge (Up to 28 days)
Secondary outcome [13] 0 0
Length of Hospital Stay from Study Treatment Initiation to Readiness for Discharge - The length of hospital stay from study treatment initiation to readiness for discharge will be reported.
Timepoint [13] 0 0
From study treatment initiation to readiness for discharge (Up to 28 days)
Secondary outcome [14] 0 0
Percentage of Participants Requiring Admission to the Intensive Care Unit (ICU) - The percentage of enrolled participants requiring admission to the ICU will be reported.
Timepoint [14] 0 0
Up to 28 days
Secondary outcome [15] 0 0
Duration of ICU Stay - In the event that a participant requires admission to the ICU, the duration for how long the participant remained in the ICU will be measured.
Timepoint [15] 0 0
Up to 28 days
Secondary outcome [16] 0 0
Percentage of Participants Requiring Oxygen Supplementation/Noninvasive Mechanical Ventilation Support - The percentage of enrolled participants requiring oxygen supplementation/noninvasive mechanical ventilation support (for example [eg], nasal cannula, face mask, continuous positive airway pressure, bilevel positive airway pressure) above pre-hMPV infection status will be reported.
Timepoint [16] 0 0
Up to 28 days
Secondary outcome [17] 0 0
Duration of Oxygen Supplementation/Noninvasive Mechanical Ventilation Support - The duration of oxygen supplementation/noninvasive mechanical ventilation support (eg, nasal cannula, face mask, continuous positive airway pressure, bilevel positive airway pressure) above pre-hMPV infection status will be measured.
Timepoint [17] 0 0
Up to 28 days
Secondary outcome [18] 0 0
Percentage of Participants Requiring Invasive Mechanical Ventilation Support - The percentage of enrolled participants requiring invasive mechanical ventilation support (eg, endotracheal-mechanical ventilation or mechanical ventilation via tracheostomy) above pre-hMPV infection status will be reported.
Timepoint [18] 0 0
Up to 28 days
Secondary outcome [19] 0 0
Duration of Invasive Mechanical Ventilation Support - The duration of invasive mechanical ventilation support (eg, endotracheal-mechanical ventilation or mechanical ventilation via tracheostomy) above pre-hMPV infection status will be measured.
Timepoint [19] 0 0
Up to 28 days
Secondary outcome [20] 0 0
Time to no Longer Requiring Supplemental Oxygen - The time to which a participant no longer requires supplemental oxygen will be measured.
Timepoint [20] 0 0
Up to 28 days
Secondary outcome [21] 0 0
Time to Clinical Stability - Time to clinical stability is defined as the time at which the following criteria are all met: normalization of blood oxygen level (return to baseline; by pulse oximetry) without requirement of supplemental oxygen beyond baseline level, normalization of oral feeding, normalization of respiratory rate and normalization of heart rate.
Timepoint [21] 0 0
Up to 28 days
Secondary outcome [22] 0 0
Number of Hours from Initiation of Study Treatment Until SpO2 is Greater Than or equal to (>=) 93 Percent (%) on Room air - The number of hours until SpO2 is >= 93% on room air among participants who were not on supplemental oxygen prior to onset of respiratory symptoms will be recorded.
Timepoint [22] 0 0
Up to 28 days
Secondary outcome [23] 0 0
Time for Respiratory Rate to Return to Pre-hMPV Infection Status - The time for respiratory rate to return to pre-hMPV infection status will be recorded.
Timepoint [23] 0 0
Up to 28 days
Secondary outcome [24] 0 0
Time for Peripheral Capillary Oxygen Saturation (SpO2) Return to Pre-hMPV Infection Status - The time for SpO2 to return to pre-hMPV infection status will be recorded.
Timepoint [24] 0 0
Up to 28 days
Secondary outcome [25] 0 0
Time for Body Temperature to Return to Pre-hMPV Infection Status - The time for body temperature to return to pre-hMPV infection status will be recorded.
Timepoint [25] 0 0
Up to 28 days
Secondary outcome [26] 0 0
Percentage of Enrolled Participants Who Require Hydration and/or Feeding by Intravenous (IV) Catheter or Nasogastric Tube - The percentage of enrolled participants who require hydration and/or feeding by intravenous (IV) catheter or nasogastric tube will be reported.
Timepoint [26] 0 0
Up to 28 days
Secondary outcome [27] 0 0
Number of Participants With Bacterial Superinfections Reported as AEs - The number of participants with bacterial superinfections, as defined by the investigator based on clinical judgment and/or increasing procalcitonin levels, reported as AEs will be reported.
Timepoint [27] 0 0
Up to 28 days
Secondary outcome [28] 0 0
Number of Participants With Treatment-Emergent Complications - The number of participants with treatment-emergent complications, including cardiovascular events and cerebrovascular events (for example, myocardial infarction, congestive heart failure exacerbation, arrhythmia, stroke) or Clostridium difficile-associated diarrhea, will be reported.
Timepoint [28] 0 0
Up to 28 days
Secondary outcome [29] 0 0
Change From Baseline in the National Early Warning Score (NEWS) Over Time - The NEWS scoring system measures acute-illness severity using 7 physiological parameters (respiration rate, oxygen saturation, supplementary oxygen requirement, temperature, systolic blood pressure, heart rate, and level of consciousness). Each parameter is scored between 0 and 3 compared to normal ranges, with higher scores indicating greater severity. The total score is the sum of the individual physiological parameter values and ranges between 0 (least severe) and 21 (most severe).
Timepoint [29] 0 0
Baseline up to 28 days
Secondary outcome [30] 0 0
Number of Participants With All-Cause Mortality - Number of participants will be assessed for all-cause mortality.
Timepoint [30] 0 0
Up to 28 days
Secondary outcome [31] 0 0
Time to Return to Pre-hMPV Infection Functional Status (Katz Activities of Daily Living [ADL] score) - Katz activities of daily living will assess questions related to Bathing, Dressing, Toileting, Transferring, Continence and Feeding. For the six individual activities, a score of 1 indicates independence, and a score of 0 indicates dependence. Total score will be calculated by adding the scores of all six activities and ranges from 0 high (participant independent) to 6 low (participant very dependent).
Timepoint [31] 0 0
Up to 28 Days
Secondary outcome [32] 0 0
hMPV Viral Load Over Time - Viral load over time will be measured in mid-turbinate nasal swabs (obtained from non-intubated participants) or in mid-turbinate nasal swabs and endotracheal samples (obtained from intubated participants or via suction through tracheostomy or other sampling methods) by qRT-PCR.
Timepoint [32] 0 0
Up to 28 days
Secondary outcome [33] 0 0
Peak hMPV Viral Load - Peak viral load over time will be measured by qRT-PCR.
Timepoint [33] 0 0
Up to 28 days
Secondary outcome [34] 0 0
Time to Peak hMPV Viral Load - Time to peak viral load as measured by qRT-PCR will be reported.
Timepoint [34] 0 0
Up to 28 days
Secondary outcome [35] 0 0
Rate of Decline of hMPV Viral Load - Rate of decline in hMPV viral load during treatment as measured by qRT-PCR will be reported.
Timepoint [35] 0 0
Up to 28 days
Secondary outcome [36] 0 0
Time to hMPV Ribonucleic Acid (RNA) Being Undetectable - Time to hMPV RNA being undetectable as measured by qRT-PCR.
Timepoint [36] 0 0
Up to 28 days
Secondary outcome [37] 0 0
Percentage of Participants With Undetectable hMPV Viral Load at Each Timepoint - Percentage of participants with undetectable viral load at each time point will be reported.
Timepoint [37] 0 0
From Day 1 to Day 7 and on Day 10, Day 14, and Day 28
Secondary outcome [38] 0 0
AUC of hMPV Viral Load From Baseline up to Day 10 - The AUC of hMPV RNA log10 viral load (measured by qRT-PCR in the mid-turbinate nasal swab specimens) is estimated by analyzing mean log10 viral load values over time using a restricted maximum likelihood based repeated measures approach.
Timepoint [38] 0 0
Baseline up to Day 10
Secondary outcome [39] 0 0
AUC of hMPV Viral Load from Baseline up to Day 14 - The AUC of hMPV RNA log10 viral load (measured by qRT-PCR in the mid-turbinate nasal swab specimens) is estimated by analyzing mean log10 viral load values over time using a restricted maximum likelihood based repeated measures approach.
Timepoint [39] 0 0
Baseline up to Day 14
Secondary outcome [40] 0 0
AUC of hMPV Viral Load in Participants Assigned to a Longer Dosing Duration From Baseline Until 1 day After the Last Dose of Study Drug - If dosing duration is increased by the Independent Data Monitoring Committee (IDMC), the AUC of hMPV viral load (measured by qRT-PCR in the mid-turbinate nasal swab specimens) will be estimated by analyzing mean log10 viral load values over time using a restricted maximum likelihood based repeated measures approach.
Timepoint [40] 0 0
Baseline Until 1 day After the Last Dose of Study Drug (approximately up to 12 days)
Secondary outcome [41] 0 0
Number of Participants With Postbaseline Changes in the hMPV Polymerase Lgene and Other Regions of the hMPV Genome Compared With Baseline Sequences - Number of participants will be assessed for postbaseline changes in the hMPV polymerase Lgene (only if no mutations are seen in the Lgene) and other regions of the hMPV genome compared with baseline sequences.
Timepoint [41] 0 0
Up to 28 days

Eligibility
Key inclusion criteria
- Participants hospitalized (or in Emergency room prior to hospitalization) at the time
of randomization and unlikely to be discharged for the first 24 hours after
randomization

- Participants diagnosed with human metapneumovirus (hMPV) infection using a rapid
polymerase chain reaction (PCR)-based molecular diagnostic assay, with or without
coinfection with another respiratory pathogen (respiratory virus or bacteria)

- Participants with an acute respiratory illness with signs and symptoms consistent with
a viral infection (for example, fever, cough, nasal congestion, runny nose, sore
throat, myalgia, lethargy, shortness of breath, or wheezing) with onset less than or
equal to (<=)5 days from the anticipated time of randomization

- With the exception of the symptoms related to hMPV infection, participants must be
medically stable on the basis of physical examination, medical history, vital signs,
and 12-lead electrocardiogram (ECG) performed at screening. If there are
abnormalities, they must be consistent with the underlying illness in the study
population, and/or the hMPV infection. This determination must be recorded in the
participant's source documents and initialed by the investigator

- A woman must have a negative urine pregnancy test (beta-human chorionic gonadotropin
[b-hCG]) at screening
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participants who are not expected to survive for more than 48 hours

- Participants who have had major thoracic or abdominal surgery in the 6 weeks prior to
randomization

- Participants who are considered by the investigator to be immunocompromised within the
past 12 months, whether due to underlying medical condition (for example, malignancy
or genetic disorder) or medical therapy (for example, medications other than
corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD) or
asthma exacerbations, chemotherapy, radiation, stem cell or solid organ transplant)

- Participants undergoing peritoneal dialysis, hemodialysis, or hemofiltration or with
an estimated glomerular filtration rate (GFR, determined by Chronic Kidney Disease
Epidemiology Collaboration [CKD-EPI] equation) of (<) 60 milliliters per minute
(mL/min) per 1.73 meter square (m^2)

- Participants with a known history of human immunodeficiency virus (HIV) or chronic
viral hepatitis

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Withdrawn
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Queen Elizabeth Hospital - Adelaide
Recruitment hospital [2] 0 0
Flinders Medical Centre - Adelaide
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Brisbane
Recruitment hospital [4] 0 0
Barwon Health - University Hospital Geelong - Geelong
Recruitment hospital [5] 0 0
Royal Melbourne Hospital - Melbourne
Recruitment hospital [6] 0 0
Mater Hospital Brisbane - South Brisbane
Recruitment hospital [7] 0 0
Westmead Hospital - Sydney
Recruitment postcode(s) [1] 0 0
5011 - Adelaide
Recruitment postcode(s) [2] 0 0
5042 - Adelaide
Recruitment postcode(s) [3] 0 0
4102 - Brisbane
Recruitment postcode(s) [4] 0 0
3220 - Geelong
Recruitment postcode(s) [5] 0 0
3050 - Melbourne
Recruitment postcode(s) [6] 0 0
4101 - South Brisbane
Recruitment postcode(s) [7] 0 0
2145 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
New Jersey
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Wisconsin
Country [7] 0 0
Argentina
State/province [7] 0 0
Bahia Blanca
Country [8] 0 0
Argentina
State/province [8] 0 0
Bahía Blanca
Country [9] 0 0
Argentina
State/province [9] 0 0
Buenos Aires
Country [10] 0 0
Argentina
State/province [10] 0 0
Ciudad De Buenos Aires
Country [11] 0 0
Argentina
State/province [11] 0 0
Ciudad De La Plata
Country [12] 0 0
Argentina
State/province [12] 0 0
Cordoba
Country [13] 0 0
Argentina
State/province [13] 0 0
La Plata
Country [14] 0 0
Brazil
State/province [14] 0 0
Porto Alegre
Country [15] 0 0
Brazil
State/province [15] 0 0
Ribeirao Preto
Country [16] 0 0
Brazil
State/province [16] 0 0
Sao Paulo
Country [17] 0 0
Brazil
State/province [17] 0 0
São Paulo
Country [18] 0 0
Bulgaria
State/province [18] 0 0
Kozloduy
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Pernik
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Troyan
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Veliko Tarnovo
Country [22] 0 0
France
State/province [22] 0 0
Bois Guillaume
Country [23] 0 0
France
State/province [23] 0 0
Caen
Country [24] 0 0
France
State/province [24] 0 0
Colombes
Country [25] 0 0
France
State/province [25] 0 0
Créteil
Country [26] 0 0
France
State/province [26] 0 0
Dijon
Country [27] 0 0
France
State/province [27] 0 0
La Tronche
Country [28] 0 0
France
State/province [28] 0 0
Nîmes
Country [29] 0 0
France
State/province [29] 0 0
Paris
Country [30] 0 0
France
State/province [30] 0 0
Poitiers
Country [31] 0 0
France
State/province [31] 0 0
St Priest En Jarez
Country [32] 0 0
France
State/province [32] 0 0
Suresnes
Country [33] 0 0
France
State/province [33] 0 0
Tours Cedex
Country [34] 0 0
Japan
State/province [34] 0 0
Fukuoka
Country [35] 0 0
Japan
State/province [35] 0 0
Gifu
Country [36] 0 0
Japan
State/province [36] 0 0
Hamamatue
Country [37] 0 0
Japan
State/province [37] 0 0
Isahaya
Country [38] 0 0
Japan
State/province [38] 0 0
Izumo
Country [39] 0 0
Japan
State/province [39] 0 0
Kitakyusyu
Country [40] 0 0
Japan
State/province [40] 0 0
Kobe-City
Country [41] 0 0
Japan
State/province [41] 0 0
Nagano
Country [42] 0 0
Japan
State/province [42] 0 0
Nagasaki
Country [43] 0 0
Japan
State/province [43] 0 0
Nagoya
Country [44] 0 0
Japan
State/province [44] 0 0
Osaka
Country [45] 0 0
Japan
State/province [45] 0 0
Ota
Country [46] 0 0
Japan
State/province [46] 0 0
Sendai
Country [47] 0 0
Japan
State/province [47] 0 0
Shiogama
Country [48] 0 0
Japan
State/province [48] 0 0
Tokai-Mura
Country [49] 0 0
Japan
State/province [49] 0 0
Tokyo
Country [50] 0 0
Japan
State/province [50] 0 0
Uruma
Country [51] 0 0
Japan
State/province [51] 0 0
Yamagata
Country [52] 0 0
Japan
State/province [52] 0 0
Yamaguchi
Country [53] 0 0
Japan
State/province [53] 0 0
Yukuhashi
Country [54] 0 0
Korea, Republic of
State/province [54] 0 0
Bucheon
Country [55] 0 0
Korea, Republic of
State/province [55] 0 0
Daegu
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Incheon
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Seongnam
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Seoul
Country [59] 0 0
Malaysia
State/province [59] 0 0
Alor Setar
Country [60] 0 0
Malaysia
State/province [60] 0 0
George Town
Country [61] 0 0
Malaysia
State/province [61] 0 0
Kota Bharu
Country [62] 0 0
Malaysia
State/province [62] 0 0
Kuala Lumpur
Country [63] 0 0
Malaysia
State/province [63] 0 0
Kuching
Country [64] 0 0
Malaysia
State/province [64] 0 0
Miri
Country [65] 0 0
Malaysia
State/province [65] 0 0
Taiping
Country [66] 0 0
Netherlands
State/province [66] 0 0
Groningen
Country [67] 0 0
Netherlands
State/province [67] 0 0
Utrecht
Country [68] 0 0
Netherlands
State/province [68] 0 0
Zutphen
Country [69] 0 0
Poland
State/province [69] 0 0
Bydgoszcz
Country [70] 0 0
Poland
State/province [70] 0 0
Checiny
Country [71] 0 0
Poland
State/province [71] 0 0
Mrozy
Country [72] 0 0
Poland
State/province [72] 0 0
Olsztyn
Country [73] 0 0
Poland
State/province [73] 0 0
Proszowice
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Engels
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Smolensk
Country [76] 0 0
Russian Federation
State/province [76] 0 0
St. Petersburg
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Tomsk
Country [78] 0 0
Russian Federation
State/province [78] 0 0
Voronezh
Country [79] 0 0
Russian Federation
State/province [79] 0 0
Yaroslavl
Country [80] 0 0
Spain
State/province [80] 0 0
Elche
Country [81] 0 0
Spain
State/province [81] 0 0
Madrid
Country [82] 0 0
Spain
State/province [82] 0 0
Santiago De Compostela
Country [83] 0 0
Spain
State/province [83] 0 0
Vigo
Country [84] 0 0
Sweden
State/province [84] 0 0
Göteborg
Country [85] 0 0
Sweden
State/province [85] 0 0
Malmö
Country [86] 0 0
Sweden
State/province [86] 0 0
Umeå
Country [87] 0 0
Sweden
State/province [87] 0 0
Uppsala
Country [88] 0 0
Taiwan
State/province [88] 0 0
Kaohsiung
Country [89] 0 0
Taiwan
State/province [89] 0 0
New Taipei
Country [90] 0 0
Taiwan
State/province [90] 0 0
Taichung
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taipei
Country [92] 0 0
Ukraine
State/province [92] 0 0
Chernivtsi
Country [93] 0 0
Ukraine
State/province [93] 0 0
Ivano-Frankivsk
Country [94] 0 0
Ukraine
State/province [94] 0 0
Kharkiv
Country [95] 0 0
Ukraine
State/province [95] 0 0
Vinnytsya

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine in hospitalized adult participants infected with
human metapneumovirus (hMPV - a virus closely related to respiratory syncytial virus (RSV)
and has been identified as an important cause of acute respiratory infections, affecting all
age groups) the dose-response relationship of multiple regimens of lumicitabine on antiviral
activity based on nasal hMPV shedding using quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) assay.
Trial website
https://clinicaltrials.gov/show/NCT03502694
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Not applicable